[The excimer laser in dermatology and esthetic medicine].
First reports about the use of the excimer laser in dermatology date back to 1997. It is seen as an improvement on conventional phototherapy and photochemotherapy because of the lower cumulative UV-dose involved, the shorter time frame required for treatment and the option of targeting individual lesions without affecting the surrounding healthy skin. In addition to the indications of psoriasis vulgaris, vitiligo and atopic eczema (for which there is now FDA approval in the US), the spectrum of possible uses for the excimer laser is growing rapidly, especially in the field of light-sensitive dermatoses. Case studies so far have ranged from post-operative hypopigmentation to acne vulgaris and from alopecia areata to parapsoriasis en plaque. The foremost priorities in the future will be to evaluate reproducible therapeutic regimens with realistic prospects of success in large-scale studies; assess potential iatrogenic risks in treatment; develop pathogenetic models for the mechanism of action; and define therapeutic approaches to new indications. This paper summarizes the publications to date and discusses our observations and experiences.
Grema
H
H
Laserklinik Karlsruhe, Karlsruhe, Germany.
Raulin
C
C
D000152:Acne Vulgaris / Q000628:therapy; D000506:Alopecia Areata / Q000628:therapy; D004954:Esthetics; D006801:Humans; D028022:Low-Level Light Therapy; D010267:Parapsoriasis / Q000628:therapy; D011565:Psoriasis / Q000628:therapy; D055502:Secondary Prevention; D012871:Skin Diseases / Q000532:radiotherapy*; D014820:Vitiligo / Q000628:therapy